Earnings per share for the last twelve months: Catalyst Pharma (CPRX)
Catalyst Pharmaceuticals (CPRX) ensures a steady capital inflow through its monopoly status in the therapy of rare syndromes. This 12-month EPS trend chart visualizes this success, where 1.73 defines the current value of the metric. Revenues are based on exclusive sales of orphan drugs in the US, while drug synthesis is fully outsourced to third-party contractors via strict SLA agreements.
Catalyst Pharma (CPRX) - metric breakdowns and financial figures
- stock price and consensus target price:
- company stock exchange capitalization indicators:
- shareholders' equity book value data:
- company total debt and liquidity indicators:
Total Debt to Equity Ratio Catalyst Pharmaceuticals|CPRX - Long-Term Loans to Capital Ratio|Short-Term Debt to Equity Ratio Catalyst Pharmaceuticals Inc|CPRX - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Catalyst Pharmaceuticals, Inc.|CPRX - Long-Term Liabilities|Company Short-Term Debts Catalyst Pharmaceuticals|Quick Ratio catalystpharma.com
- earnings and valuation multiples indicators:
CPRX - Net Profit|Expected Profit Catalyst Pharmaceuticals|CPRX - Company Value to Net Income|Future Price to Earnings Catalyst Pharmaceuticals, Inc.|CPRX - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Catalyst Pharmaceuticals, Inc.|CPRX - Operating profit EBITDA|Net earnings per share (EPS TTM) Catalyst Pharmaceuticals|CPRX - Net earnings per share for the last 12 months|Quarterly EPS earnings growth catalystpharma.com|CPRX - Earnings per share growth rate in current year|Expected earnings per share growth for next year Catalyst Pharmaceuticals
General company analysis:CPRX - Catalyst Pharmaceuticals
Amid inflationary pressure, business resilience to external shocks is determined by the ability to generate real cash flow per share. The robotization of orphan drug logistics via third-party capacities for Catalyst Pharmaceuticals (CPRX) reduces costs, which is reflected in the trailing 12-month earnings per share trend, measuring annual net income with daily recalculations to capture fundamental reversals prior to official reports.
Key competitors
Biogen Inc. - Net earnings per share (EPS TTM)|NBIX - Net earnings per share (EPS TTM)|Regencell Bioscience Holdings Limited (RGC) - Earnings per share for the last twelve months|AXSM (Axsome) - Earnings per share for the last twelve months|Net earnings per share for the last 12 months ACAD|Net earnings per one share for the last twelve months Xenon Corp XENE|Earnings per share for the last twelve months Viking Therapeutics (VKTX)|Net earnings per share for the last four quarters supernus.com|Denali Therapeutics Inc. - Net earnings per share for the last 12 months|Earnings per share for the last four quarters HRMY (Harmony Biosciences Inc)|BHVN: Net earnings per share for the last 12 months|Earnings per share for the trailing year AMLX (Amylyx Corp)|Trevi Therapeutics (TRVI) - Earnings per share for the last twelve months|Earnings per one share for the last 12 months PRAX (praxismedicines.com)|AVXL (Anavex Life Sciences Corp.) - Net earnings per share (EPS TTM)|CBLL: Earnings per share for the trailing year|Net earnings per share (EPS TTM) PRTA|Net earnings per share (EPS TTM) alector.com (ALEC)|Earnings per share for the last twelve months Annexon, Inc. ANNX|Earnings per share for the trailing year OMER|NGNE - Earnings per share for the last twelve months|AC Immune S.A. (ACIU) - Net earnings per share for the last 12 months|VYGR: Net earnings per share (EPS TTM)|Neumora Corp (NMRA) - Net earnings per share (EPS TTM)|SCLX (Scilex Holding Company) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months tevogen.com (TVGN)|Net earnings per share (EPS TTM) ACOG|CGTX - Net earnings per one share for the last twelve months|Inhibikase - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Cassava Pharma SAVA|ASRT: Net earnings per share for the last 12 months|Coya Therapeutics, Inc. - Earnings per share for the last four quarters|VTGN: Net earnings per share (EPS TTM)|OVID - Net earnings per share for the last four quarters|ABOS (Acumen Pharma) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months CervoMed Corporation (CRVO)|Net earnings per share (EPS TTM) ATHE|Net earnings per share (EPS TTM) clene.com (CLNN)|Earnings per share for the last twelve months PepGen PEPG|Jupiter Neurosciences, Inc. - Earnings per share for the last twelve months|RLMD - Earnings per share for the last twelve months|Net earnings per share for the last four quarters Annovis Bio Corporation ANVS|GRCE: Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months fireflyneuro.com|Earnings per share for the last twelve months ANEW Medical|NeuroSense Therapeutics, Ltd. - Earnings per one share for the last 12 months|Earnings per share for the last twelve months Reviva Pharmaceuticals Holdings (RVPH)|MTVA (metaviatx.com) - Earnings per share for the trailing year|NeurAxis, Inc. - Net earnings per share for the last 12 months|HSDT: Earnings per share for the last 12 months|PASG - Earnings per share for the last twelve months|NEUP (Neuphoria Therapeutics Inc.) - Earnings per share for the last 12 months|NERV: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Athira Pharma Corp (ATHA)|Net earnings per share for the last 12 months ADXN|Net earnings per share (EPS TTM) Alzamend|Earnings per share for the last twelve months Cyclerion Therapeutics (CYCN)|PTIX (protagenic.com) - Earnings per share for the trailing year|Earnings per share for the last twelve months Pasithea Therapeutics Corp. KTTA|Cortigent Inc (CRGT) - Net earnings per one share for the last twelve months|Avenue Therapeutics - Net earnings per share (EPS TTM)|brainstorm-cell.com (BCLI) - Net earnings per share for the last 12 months|CARA: Net earnings per share (EPS TTM)|Chromocell Therapeutics Corp (CHRO) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months ELYM|ITCI (Intra-Cellular) - Earnings per share for the last four quarters|Net earnings per share (EPS TTM) LBPH|Net earnings per share (EPS TTM) marinuspharma.com (MRNS)|Earnings per share for the last twelve months NKGen Biotech NKGN|NeuroBo Pharmaceuticals Inc - Earnings per share for the last twelve months|SAGE: Net earnings per share for the last 12 months|Net earnings per one share for the last twelve months Synaptogenix, Inc|Trevena, Inc. (TRVN) - Earnings per share for the last twelve months|VIGL - Net earnings per share for the last four quarters|Net earnings per share for the last 12 months WENA|CERE (Cerevel Therapeutics Inc) - Earnings per share for the last four quarters
